BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR
To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 77CR. Overall design: LuCaP 77CR tumors were treated with enzalutamide, pelabresib or a combination of pelabresib and enzalutamide and tumor volumes were compared to vehicle control